Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 8/20 | 0.42 |
| ▸ | ESR1 | P03372 | 3/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.39 |
| ▸ | LIMK1 | P53667 | 4/20 | 0.38 |
| ▸ | CLK1 | P49759 | 1/20 | 0.37 |
| ▸ | AGXT | P21549 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23555788 | 0.96 | KIF11 (0.45) | KIF11ESR1SLC6A2P2RY14LIMK1 | |
| SCHEMBL12062903 | 0.96 | KIF11 (0.45) | KIF11ESR1SLC6A2P2RY14LIMK1 | |
| SCHEMBL23556059 | 0.89 | KIF11 (0.47) | KIF11ESR1SLC6A2P2RY14LIMK1 | |
| SCHEMBL23556055 | 0.89 | KIF11 (0.47) | KIF11ESR1SLC6A2P2RY14LIMK1 | |
| SCHEMBL12055731 | 0.89 | KIF11 (0.39) | KIF11ESR1SLC6A2P2RY14LIMK1 | |
| SCHEMBL21180998 | 0.83 | ESR1 (0.38) | KIF11ESR1CLK1 | |
| SCHEMBL23555814 | 0.80 | KIF11 (0.42) | KIF11LIMK1AGXT | |
| SCHEMBL23555810 | 0.79 | KIF11 (0.41) | KIF11ESR1LIMK1 | |
| SCHEMBL23555677 | 0.79 | KIF11 (0.40) | KIF11ESR1 | |
| SCHEMBL24619537 | 0.78 | LIMK1 (0.54) | LIMK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138355-B2 | Heteroacene derivative, tetrahaloterphenyl derivative, and processes for producing the same | TOSOH CORPORATION (JP) | 2012-03-20 | — | — | US | disclosed |
| US-8138355-B2 | Heteroacene derivative, tetrahaloterphenyl derivative, and processes for producing the same | TOSOH CORPORATION (JP) | 2012-03-20 | — | — | US | disclosed |
| US-20090261300-A1 | HETEROACENE DERIVATIVE, TETRAHALOTERPHENYL DERIVATIVE, AND PROCESSES FOR PRODUCING THE SAME | TOSOH CORPORATION (JP) | 2009-10-22 | — | — | US | disclosed |
| US-20090261300-A1 | HETEROACENE DERIVATIVE, TETRAHALOTERPHENYL DERIVATIVE, AND PROCESSES FOR PRODUCING THE SAME | TOSOH CORPORATION (JP) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090261300-A1 | HETEROACENE DERIVATIVE, TETRAHALOTERPHENYL DERIVATIVE, AND PROCESSES FOR PRODUCING THE SAME | AS3MT, TERT, TEAD1 | KIF11 4696/4885ESR1 643/4885SLC6A2 668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.